Table 1: Characteristics of eligible studies.

StudyCountryCancer typeDurationNumberMethodPercentFollow-up assessmentQuality

Bektas et al. 2008 [16]GermanyBC1994–2002204IHC72.3%SC0.80 (0.30–2.11)9
Sanders et al. 2013 [11]UKBC; ER+NR455Microarray49.9%HR3.51 (2.12–5.81)9
Bergamaschi et al. 2014 [21]USABC; ER+NR501IHC20.2%SC2.29 (1.61–3.24)8
Ahn et al. 2013 [22]KoreaBC; ER+1997–200781Microarray29.6%SC6.80 (1.28–36.08)8
He et al. 2012 [12]ChinaCervical cancer; early-stage2002–2005102IHC73.5%SC1.11 (0.33–3.75)9
Li et al. 2013 [23]ChinaColon cancer;2001–2003203IHC75.8%HR3.62 (1.91–6.88)10
Chu et al. 2012 [24]ChinaColorectal cancer2002–2004112IHC50.9%HR2.03 (1.18–2.66)10
Takata et al. 2014 [25]JapanEsophageal cancer2001–2007174IHC50%HR1.69 (1.06–2.75)10
Wang et al. 2013 [26]ChinaGallbladder cancer2002–200776IHC56.6%SC1.81 (1.05–3.12)9
Okada et al. 2013 [14]JapanGC2001–200877IHC68.8%HR3.9 (1.1–24.7)9
Hu et al. 2015 [27]ChinaGCNR40IHC65%SC1.96 (0.27–14.19)7
Li et al. 2013 [28]ChinaGC2007103IHC78.6%SC1.98 (0.84–4.66)9
Zhang et al. 2012 [29]ChinaGlioblastomaNR38IHC71.1%SC2.70 (0.89–8.18)7
Xia et al. 2012 [13]ChinaHCC1999–2001306IHC65.7%HR1.53 (1.10–2.12)10
Sun et al. 2011 [30]ChinaHCC2001–200999IHC42.4%SC3.59 (1.14–11.24)8
Sun et al. 2011 [31]ChinaHCC2001–2008150IHC59.3%SC4.04 (2.02–8.09)9
Meng et al. 2015 [32]ChinaHCC2006–2010172IHC62.2%SC1.87 (1.10–3.17)9
Jiang et al. 2011 [33]ChinaLaryngeal SCC2002–200389IHC78.7%SC1.35 (0.36–5.07)8
Xu et al. 2012 [34]ChinaNSCLC2005–2008201IHCNRHR1.96 (1.04–3.17)10
Chen et al. 2014 [35]TaiwanNSCLC1993–2004117IHC60.7%HR1.74 (1.06–2.86)10
Xu et al. 2013 [15]ChinaNSCLC2005–2008175IHC64%HR1.899 (1.016–3.551)10
Yang et al. 2009 [36]KoreaNSCLC2000–200469IHC37.7%SC2.38 (0.74–7.68)8
Kong et al. 2014 [37]ChinaNSCLC2004–200668IHC63.2%HR2.95 (1.036–8.397)9
Wang et al. 2013 [38]ChinaNSCLC; stage IIIb-IV2004–2007162IHC71.6%SC1.50 (1.01–2.22)9
Liu et al. 2011 [39]ChinaNSCLC2004–200868IHC36.8%SC2.36 (1.13–4.93)8
Yu et al. 2011 [40]USAMPNSTNR82IHC70.8%HR1.93 (1.12–3.31)8
Priller et al. 2011 [41]GermanyMedulloblastomaNR130IHC33.8%HR2.24 (1.05–4.77)9
Chen et al. 2014 [35]TaiwanOral cancer1993–2004110IHC43.6%HR4.70 (2.50–8.87)10
Wen et al. 2014 [42]ChinaOC2009–2011158IHC63.9%HR1.494 (1.007–2.215)10
Zhao et al. 2014 [43]ChinaOC1987–200482IHC64.6%SC1.12 (0.40–3.15)8
Chiu et al. 2015 [44]TaiwanOC1993–2010106IHC44.3%SC0.96 (0.43–2.16)9
Ning et al. 2014 [45]ChinaPDA; stage II2002–2013136IHC63.2%HR1.270 (0.713–2.830)10
Xia et al. 2012 [46]ChinaPDA2003–200780IHC66.3%SC4.99 (1.50–16.55)8
Li et al. 2014 [47]ChinaPDANR50IHC56%SC1.61 (0.64–4.04)7
Xue et al. 2012 [48]ChinaCCRCC2004–200883IHC45.8%SC3.58 (1.20–10.74)8
Wu et al. 2013 [49]ChinaCCRCC2006–201087IHC42.5%HR3.97 (1.10–14.35)9

BC: breast cancer; GC: gastric cancer; HCC: hepatocellular carcinoma; SCC: squamous cell carcinoma; NSCLC: non-small-cell lung cancer; MPNST: malignant peripheral nerve sheath tumor; OC: ovarian cancer; PDA: pancreatic ductal adenocarcinoma; CCRCC: clear cell renal cell carcinoma; NR: Not Report; IHC: immunohistochemistry; HR: hazard ratio; SC: survival curve; ER(+): Estrogen Receptor (+).